Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients

Transplant Infectious Disease

Volumn 16, Issue 6, 2014, Pages 941-950

  Gagermeier, J P ^a   Rusinak, J D ^a   Lurain, N S ^b   Alex, C G ^a,c   Dilling, D F ^a   Wigfield, C H ^d   Love, R B ^e  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY   (United States)

^c ADVOCATE CHRIST MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cytomegalovirus; Ganciclovir resistance; Lung transplantation

Indexed keywords

ANTIVIRAL AGENTS; GANCICLOVIR;

ADULT; ADVERSE EFFECTS; AGED; BLOOD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; VIRAL LOAD; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84920181776     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12317     Document Type: Article

References (35)

1. Ettinger N, Bailey T, Trulock E, et al. Cytomegalovirus infection and pneumonitis: impact after isolated lung transplantation. Am Rev Respir Dis 1993; 147: 1017-1023.
2. Duncan S, Grgurich W, Iacono A, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994; 150: 146-152.
3. Fishman J, Rubin R. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751.
4. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis 2001; 3 (3): 128-137.
5. Calhoon J, Nichols L, Davis R, et al. Single lung transplantation: factors in postoperative cytomegalovirus infection. J Thorac Cardiovasc Surg 1992; 103: 21-26.
6. Limaye A, Raghue G, Koelle D, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185 (1): 20-27.
7. Reddy A, Zaas A, Hanson K, et al. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. J Heart Lung Transplant 2007; 26 (12): 1286-1292.
8. Bhorade S, Jordan A, Leischner J, et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002; 21 (12): 1274-1282.
9. Jamil B, Nicholls K, Becker G, et al. Influence of anti-rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipients. Clin Transplant 2000; 14 (1): 14-18.
10. Kruger R, Shannon S, Arens M, et al. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 1999; 68 (9): 1272-1279.
11. Limaye A, Corey L, Koelle D, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-649.
12. Garcia-Martinez J, Folgueira L, Delgado R, et al. Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection in a heart transplant recipient. Transpl Infect Dis 2008; 10 (2): 123-128.
13. Hanson K, Reller R, Kurtzberg J, et al. Comparison of the Digene Hybrid Capture System cytomegalovirus (CMV) DNA (version 2.0), Roche CMV UL54 analyte-specific reagent, and QIAGEN RealArt CMV LightCycler PCR reagent tests using Acrometrix Optiquant CMV DNA quantification panels and specimens from allogeneic-stem-cell transplant recipients. J Clin Microbiol 2007; 45: 1972-1973.
14. Caliendo A, Ingersoll J, Fox-Canale A, et al. Evaluation of real-time PCR laboratory-developed tests using analyte-specific reagents for cytomegalovirus quantification. J Clin Microbiol 2007; 45: 1723-1727.
15. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
16. VALCYTE(R) PI. Roche Pharmaceuticals: 2009.
17. Kotton C, Kumar D, Caliendo A, et al.; Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89 (7): 779-795.
18. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid organ translant patient with CMV disease. J Infect Dis 2002; 186 (6): 829-833.
19. Landry M, Chou S, Lurain N, et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 2000; 44 (3): 688-692.
20. Sullivan V, Biron K, Talarico C, et al. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother 1993; 37 (1): 19-25.
21. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Update 2002; 5 (2): 88-114.
22. Smith I, Cherrington J, Jiles R, et al. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176 (1): 69-77.
23. Jacobson M, Drew W, Feinberg J, et al. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis 1991; 163: 1348-1351.
24. Thomas J, Forrest A, Bhavnani S, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42 (3): 521-527.
25. Emery V, Griffiths P. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 2000; 97 (14): 8039-8044.
26. Bronstein M, Sokol R, Abman S, et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 1992; 120 (4 Pt 1): 533-540.
27. Zentler-Munro P. Pancreatic exocrine insufficiency and cystic fibrosis. Curr Opin Gastroenterol 1989; 5: 706-710.
28. Yaffe S, Gerbracht L, Mosvich L, et al. Pharmacokinetics of methicillin in patients with CF. J Infect Dis 1977; 155 (5): 828-831.
29. Susanto M, Benet L. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res 2002; 19 (4): 457-462.
30. Bain L, McLachlan J, LeBlanc G. Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. Environ Health Perspect 1997; 105 (8): 812-818.
31. Wang R, Kuo C, Lien L, et al. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 2003; 28 (3): 203-228.
32. Gottesman M, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
33. Kiser TH, Fish DN, Zamora MR. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. J Heart Lung Transplant 2012; 31 (2): 159-166.
34. Lefeuvre S, Chevalier P, Charpentier S, et al. Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure. Transpl Infect Dis 2010; 12 (3): 213-219.
35. Perrottet N, Decosterd L, Meylan P, et al. Valganciclovir in adult solid organ transplant recipients. Clin Pharmacokinet 2009; 48: 399-418.